AstraZeneca agrees to pay up to £4.7bn for cancer drug

UK-based company hopes deal with Daiichi Sankyo will lead to new breast and lung cancer treatment

AstraZeneca has agreed a deal worth as much as £4.7bn with a Japanese drug company to develop and market a potential new cancer treatment.

The British–Swedish pharmaceutical company said it would pay $1bn (£800m) upfront to its partner, Daiichi Sankyo, in what is the latest of a series of bets by the pharma company on oncology treatments.

Continue reading…

Source link